Inactivated Vaccines Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Inactivated Vaccines Market Poised To Hit $8.06 Billion By 2030 With A 5.1% CAGR
The inactivated vaccines market size has experienced steady expansion in recent years. Its valuation is anticipated to rise from $6.37 billion in 2025 to $6.61 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 3.9%. The market’s historic growth can be ascribed to factors like an increasing prevalence of infectious diseases, developments in virology research, government funding for immunization efforts, the expansion of healthcare infrastructure, and public awareness campaigns promoting vaccination.
The inactivated vaccines market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $8.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This growth trajectory throughout the forecast period stems from factors such as an expanding elderly demographic, improved healthcare accessibility in developing economies, innovations in vaccine delivery mechanisms, a surge in worldwide immunization efforts, and the increasing uptake of multi-dose and combination vaccines. Key developments expected during this timeframe encompass improvements in vaccine creation methods, an expansion of cold chain logistical networks, a rising need for childhood vaccines, the proliferation of governmental immunization schemes, and the ongoing creation of combined vaccines.
Get A Free Sample Report With In-Depth Market Insights:
Inactivated Vaccines Market Development Factors: What’s Supporting Demand?
The rising occurrence of infectious diseases is projected to drive the expansion of the inactivated vaccine market going forward. Infectious diseases are conditions caused by agents such as bacteria, viruses, fungi, or parasites that can spread between people, leading to various symptoms and health complications, with tuberculosis being one example. Inactivated vaccines employ non-living pathogens to induce an immune response, thereby preventing diseases like polio, hepatitis A, and influenza. For example, in November 2023, the Centers for Disease Control and Prevention, a national public health agency based in the USA, reported that the number of tuberculosis patients in the USA increased from 8,320 in 2022 to 9,615 in 2023, indicating an increase of 1,295 cases. Hence, the increasing prevalence of infectious diseases is fueling the growth of the inactivated vaccine market.
Inactivated Vaccines Market Segment Performance And Emerging Opportunities
The inactivated vaccines market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent, Radiation, pH Concentration, Heat Inactivation, Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
Subsegments:
1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV), Inactivated Influenza Vaccine, Inactivated Hepatitis A Vaccine, Inactivated Rabies Vaccine
2) By Bacterial Vaccine: Inactivated Typhoid Vaccine, Inactivated Cholera Vaccine, Inactivated Pertussis Vaccine, Inactivated Plague Vaccine
Inactivated Vaccines Market Transformation Trends: What Innovations Are Driving Change?
Major companies operating in the inactivated vaccines market are concentrating on expanding their product launches and securing regulatory approvals to strengthen their global vaccine portfolios and meet increasing immunization requirements. For instance, in April 2024, Sanofi S.A., a France-based healthcare company, introduced Verorab, its inactivated rabies vaccine, in the UK, suitable for all age groups in both pre-exposure and post-exposure situations. This introduction highlights the company’s ongoing commitment to expanding its range of inactivated vaccines and enhancing its global immunization offerings. This initiative also reflects growing investments and increasing regulatory momentum surrounding inactivated vaccine development and approvals. As more companies advance similar products and diversify their portfolios, these strategic actions are collectively driving significant growth in the inactivated vaccines market, supporting broader protection against infectious diseases.
Inactivated Vaccines Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the inactivated vaccines market are Pfizer Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.
View The Full Inactivated Vaccines Market Report:
Inactivated Vaccines Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the inactivated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
